Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma: three-year survival of a prospective, randomized, open-label trial. Ann Surg 2018; 267: 826-832.
Published: 9th August 2018
Authors: Li B, Hu H, Zhang Y, Zhang J, Miao L, Ma L et al.
In the study that included 286 patients followed for a median of 55.9 months, three year disease-free survival was 62% after right thoracotomy versus 52% after left thoracotomy (P=0.047). Respective overall survival rates were 74 and 60%, P=0.029.Pubmed Link
You may also be interested in
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.
Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.
Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer. A randomized controlled trial. Ann Surg 2019; 269: 621-630.
Authors: van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens L, Joore HC et al.
Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery. A randomized clinical trial. JAMA Surg 2018; 153: 1081-1089.
Authors: Minnella EM, Awasthi R, Loiselle S-E, Agnihotram RV, Ferri LE, Carli F et al.
Authors: Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D et al.
Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.
Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.
The RESTORE randomized controlled trial: impact of a multidisciplinary rehabilitative program on cardiorespiratory fitness in esophagogastric cancer survivorship. Ann Surg 2008; 268: 747-755.
Authors: O’Neill L, Guinan E, Doyle S, Bennett AE, Murphy C, Elliott JA et al.
Early oral feeding following McKeown minimally invasive esophagectomy: an open-label, randomized, controlled, noninferiority trial. Ann Surg 2018; 267: 435-442.
Authors: Sun H-B, Li Y, Liu X-B, Zhang R-X, Wang Z-F, Lerut T et al.
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.
Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.
Circular stapling versus triangulating stapling for the cervical esophagogastric anastomosis after esophagectomy in patients with thoracic esophageal cancer: A prospective, randomized, controlled trial. Surgery 2017; 162: 131-138.
Authors: Hayata K, Nakamori M, Nakamura M, Ojima T, Iwahashi M, Katsuda M et al.
Does prolonged enteral feeding with supplemental omega-3 fatty acids impact on recovery post-esophagectomy: results of a randomized double-blind trial. Ann Surg 2017; 266: 720-728.
Authors: Healy LA, Ryan A, Doyle S, Ní Bhuachalla EB, Cushen S, Segurado R et al.
Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: The TIME Trial. Ann Surg 2017; 266: 232-236.
Authors: Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, Bonavina L et al.
Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.
Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.